Johnson & Johnson (NYSE:JNJ) Shares Sold by Perigon Wealth Management LLC

Perigon Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,056 shares of the company’s stock after selling 3,408 shares during the quarter. Perigon Wealth Management LLC’s holdings in Johnson & Johnson were worth $13,160,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Johnson & Johnson during the second quarter worth approximately $49,000. AMF Tjanstepension AB boosted its holdings in shares of Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Czech National Bank grew its position in shares of Johnson & Johnson by 6.9% in the third quarter. Czech National Bank now owns 490,381 shares of the company’s stock valued at $79,471,000 after purchasing an additional 31,766 shares during the period. Wiser Wealth Management Inc purchased a new position in Johnson & Johnson during the third quarter worth about $260,000. Finally, Park Avenue Securities LLC boosted its stake in Johnson & Johnson by 14.9% in the 3rd quarter. Park Avenue Securities LLC now owns 82,287 shares of the company’s stock worth $13,335,000 after buying an additional 10,664 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JNJ. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays increased their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ opened at $152.09 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a 50-day moving average price of $147.67 and a 200 day moving average price of $156.07. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $366.17 billion, a P/E ratio of 22.87, a P/E/G ratio of 2.43 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.26%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.